freeline
announces
supply
agreement
haemophilia
b
program
london
globe
newswire
freeline
therapeutics
holdings
plc
nasdaq
frln
company
freeline
clinical
stage
next
generation
systemic
gene
therapy
company
ambition
transforming
lives
patients
suffering
inherited
systemic
debilitating
diseases
today
announces
supply
agreement
thermo
fisher
scientific
thermo
fisher
agreement
secures
dedicated
production
capacity
resources
freeline
inclusive
provide
capacity
planned
phase
pivotal
clinical
trial
potential
commercialisation
freeline
haemophilia
b
program
using
company
proprietary
manufacturing
platform
processes
freeline
established
manufacturing
process
thermo
fisher
cambridge
facility
past
two
years
recently
initiating
clinical
supply
production
planned
phase
pivotal
clinical
trial
delighted
announce
significant
extension
partnership
thermo
fisher
said
jan
thirkettle
chief
development
officer
freeline
investment
commitment
thermo
fisher
viral
vector
services
operation
gives
us
great
confidence
right
partner
enable
us
commercialise
haemophilia
b
therapy
demand
new
gene
therapies
continues
grow
made
strategic
investments
expand
viral
vector
commercial
manufacturing
capabilities
provide
customers
uninterrupted
pathway
development
commercialisation
great
example
work
freeline
support
program
develop
novel
treatment
haemophilia
b
pleased
partner
said
chris
murphy
vice
president
general
manager
thermo
fisher
viral
vector
services
business
freeline
freeline
biotechnology
company
focused
gene
therapy
targeting
liver
vision
create
better
lives
people
suffering
chronic
systemic
diseases
using
potential
gene
therapy
treatment
provide
potential
functional
cure
freeline
headquartered
operations
germany
haemophilia
haemophilia
genetic
bleeding
disorder
protein
made
body
help
make
blood
clot
either
partly
completely
missing
protein
called
clotting
factor
haemophilia
deficiency
clotting
factor
viii
eight
protein
haemophilia
b
deficiency
clotting
factor
ix
nine
protein
haemophilia
mainly
affects
boys
men
however
women
carriers
affected
gene
may
experience
symptoms
haemophilia
common
type
haemophilia
affecting
one
every
males
haemophilia
b
affects
one
every
males
haemophilia
classified
mild
moderate
severe
depending
level
clotting
factor
viii
ix
blood
diagnosed
blood
tests
freeline
haemophilia
b
program
uses
synthetic
capsid
gain
function
variant
human
factor
ix
fix
therapy
currently
studied
phase
trial
goal
normalising
fix
activity
patients
moderate
severe
haemophilia
statements
press
release
contains
statements
constitute
forward
looking
statements
term
defined
united
states
private
securities
litigation
reform
act
including
statements
express
company
opinions
expectations
beliefs
plans
objectives
assumptions
projections
regarding
future
events
future
results
contrast
statements
reflect
historical
facts
examples
include
discussion
company
strategies
financing
plans
clinical
trial
plans
cases
identify
statements
terminology
anticipate
intend
believe
estimate
plan
seek
project
expect
may
would
could
negative
terms
similar
expressions
forward
looking
statements
based
management
current
beliefs
assumptions
information
currently
available
company
place
undue
reliance
statements
statements
subject
many
risks
uncertainties
including
company
recurring
losses
operations
development
company
product
candidates
including
statements
regarding
timing
initiation
completion
outcome
clinical
studies
trials
related
preparatory
work
company
ability
design
implement
successful
clinical
trials
product
candidates
potential
pandemic
epidemic
outbreak
infectious
diseases
eu
including
pandemic
disrupt
company
clinical
trial
pipeline
company
failure
demonstrate
safety
efficacy
product
candidates
fact
results
obtained
earlier
stage
clinical
testing
may
indicative
results
future
clinical
trials
company
ability
enrol
patients
clinical
trials
product
candidates
possibility
one
company
product
candidates
may
cause
serious
adverse
undesirable
unacceptable
side
effects
properties
could
delay
prevent
regulatory
approval
limit
commercial
potential
company
ability
obtain
maintain
regulatory
approval
product
candidates
company
limited
manufacturing
experience
could
result
delays
development
commercialization
product
candidates
company
ability
identify
discover
additional
product
candidates
failure
capitalize
programs
product
candidates
risks
uncertainties
may
cause
statements
inaccurate
readers
cautioned
place
undue
reliance
statements
many
risks
outside
company
control
could
cause
actual
results
differ
materially
thought
would
occur
statements
included
press
release
made
date
hereof
company
undertake
specifically
declines
obligation
update
statements
publicly
announce
results
revisions
statements
reflect
future
events
developments
except
required
law
information
please
reference
company
reports
documents
filed
securities
exchange
commission
may
get
documents
visiting
edgar
sec
website
information
jw
communications
julia
wilson
juliawilsonuk
